Is Skin Cancer Covered by the 9/11 Victim Compensation Fund?

Who qualifies for 9/11 skin cancer compensation?

Anyone diagnosed with a 9/11-related skin cancer following presence in the New York City exposure zone, at the Pentagon, or in Shanksville, Pennsylvania during the covered period may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from a 9/11-related skin cancer. Non-melanoma skin cancer is currently the largest certified cancer category in the WTCHP, and diagnoses continue to rise each year.

What skin cancers does the VCF cover?

The WTC Health Program certifies both non-melanoma and melanoma skin cancers as 9/11-related conditions. Each type is evaluated on its own medical evidence and carries its own baseline award under the VCF's non-economic loss framework.

Non-melanoma skin cancer (BCC and SCC)

Non-melanoma skin cancer refers primarily to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). These are the most common skin cancers in the 9/11 community and worldwide. Both types are typically treated with a localized excision, rarely metastasize, and are grouped together for VCF award purposes at the $90,000 baseline. Awards are not calculated based on each separate site or type of non-melanoma cancer: multiple non-melanoma diagnoses in the same claim, whether both BCC and SCC, the same type at more than one site, or a recurrence at a previous site, are generally awarded at the $90,000 level in total.

Melanoma of the skin

Melanoma is a more aggressive form of skin cancer that carries a meaningfully higher risk of spreading if not caught early. All four melanoma subtypes are covered by the WTCHP, including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. Because melanoma is evaluated on its own higher-severity footing, the VCF's baseline non-economic loss award for melanoma is $250,000, which is the statutory maximum for a single cancer condition. For melanoma-specific detail on staging, prognosis, and compensation, see our dedicated melanoma page.

Rare and other skin cancers

Other, rarer cancers that affect the skin are also covered. Merkel cell carcinoma and scrotal cancer are covered under the WTCHP's rare-cancer framework, and mycosis fungoides, a lymphoma that arises in the skin, is covered as a certified lymphoma. If your diagnosis is not listed on this page, see the full list of covered conditions or request a free case review.

More than 400,000 people are estimated to have been exposed to 9/11 toxins in the New York Exposure Zone alone, with additional exposures at the Pentagon and Shanksville, Pennsylvania. Downtown workers, area residents, students, first responders, cleanup crews, and volunteers each experienced different exposure patterns, but all encountered the same underlying mixture of dust, smoke, and debris released by the collapse of the World Trade Center.

Government-led studies of settled dust and air samples identified asbestos, silica, polycyclic aromatic hydrocarbons, dioxins, furans, heavy metals, and other hazardous substances at the three 9/11 sites. Skin was exposed to these carcinogens both directly, as particles settled on unprotected skin and were held in place by sweat and clothing, and indirectly through repeated ambient contact over the days, weeks, and months following September 11. For responders and cleanup workers, skin exposure was often prolonged; for residents and workers who returned to Lower Manhattan in the days after the attacks, exposure was continuous even without direct site work.

Skin cancer does not appear immediately after exposure to a carcinogen. There is typically a period of years between exposure and diagnosis, known as latency, during which cellular damage accumulates. This is why the WTC Health Program requires a minimum four-year latency period between the first date of exposure to 9/11 toxins and first date of diagnosis to certify a skin cancer as 9/11-related.

Certification does not require proof that 9/11 exposure was the only cause of a particular skin cancer. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition. Other risk factors, including sun exposure, fair skin, and family history, do not preclude certification.

Skin cancer symptoms differ meaningfully between non-melanoma and melanoma. The checklists below summarize the most common presentations. Any suspicious skin change should be evaluated by a WTC Health Program participating dermatologist.

Symptoms of non-melanoma skin cancer (BCC and SCC)

• A new growth, sore, or lesion that does not heal within a few weeks
• A pearly, waxy, or translucent bump on the face, ears, or neck
• A firm, red nodule or a flat lesion with a scaly, crusted surface
• A raised growth with a rolled edge and a central depression that may bleed
• A rough, scaly patch on sun-exposed skin (actinic keratosis, a precursor to SCC)
• A wart-like growth that crusts or bleeds
• A scar-like area of skin where no injury occurred

Symptoms of melanoma (ABCDE)

Melanoma is evaluated using the ABCDE framework developed by the American Cancer Society:

• Asymmetry — one half of the mole or spot does not match the other
• Border — edges are irregular, ragged, notched, or blurred
• Color — inconsistent shades of brown, black, tan, red, white, or blue
• Diameter — larger than 6 millimeters (about the size of a pencil eraser), though melanomas can be smaller
• Evolving — the mole or spot changes in size, shape, color, or elevation, or a new symptom develops such as bleeding, itching, or crusting

Any mole or lesion that meets one or more ABCDE criteria should be evaluated promptly. Melanoma detected early is highly treatable; detected late, it carries a substantially higher risk of spreading.

The WTC Health Program requires a minimum four-year latency period between the first date of 9/11 exposure and first date of diagnosis for both melanoma and non-melanoma skin cancer. This latency requirement is set by federal regulation and has no exceptions. Skin cancers diagnosed less than four years after first exposure cannot be certified.

Most skin cancer claimants meet the four-year latency requirement on its face. For a majority of people, the first 9/11 toxin exposure occurred in September 2001 or in the weeks and months following, meaning skin cancer diagnosed from roughly September 2005 forward may satisfy the latency requirement depending on the claimant's first day of exposure. Diagnoses from 2010, 2015, 2020, or today are all well past the latency threshold.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the skin cancer as 9/11-related, not from the date of diagnosis. Prior diagnoses from earlier years remain eligible if WTCHP certification occurs and the VCF claim is registered within the applicable two-year window. The claimant then still has until 2090 to actually compile other required documentation and submit their claim for eligibility and compensation review. The VCF is authorized to accept claims through October 1, 2090.

What compensation is available for 9/11 skin cancer?

Certified 9/11 skin cancer qualifies claimants for two forms of support: free medical treatment through the WTC Health Program, and financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss awards for skin cancer are published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.

Baseline non-economic loss awards

• Non-melanoma skin cancer (BCC and SCC): $90,000. This baseline applies whether the claim involves basal cell carcinoma, squamous cell carcinoma, the same type at more than one site, multiple diagnoses of both types, or a recurrence at a previous site. Multiple non-melanoma diagnoses for one Claimant generally result in a total award of $90,000.
• Melanoma: $250,000. This is the statutory maximum non-economic loss award for a single cancer condition. Melanoma is evaluated on its own higher-severity footing than other skin cancers based on the greater medical risk it carries.
• Combined melanoma and non-melanoma: $300,000. When both are certified on the same claim, the VCF does not calculate an award by simply adding the value of each type of skin cancer. Instead, the combination of non-melanoma and melanoma skin cancer results in an award of $300,000.

Above-baseline non-melanoma awards

A non-melanoma skin cancer award above the $90,000 baseline is technically possible but rare. It typically requires an extensive medical record demonstrating ongoing and frequent recurrences or metastasis, and permanent complications resulting from those diagnoses and/or from treatment that go well beyond a routine excision. Above-baseline awards generally require a compensation appeal hearing, at which the claimant testifies about the long-term impact of the condition on daily life.

Other forms of compensation

In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts, as well as wrongful death compensation to the personal representatives of individuals who died from a 9/11-related skin cancer. Attorney fees for VCF claims are capped at 10% by federal statute.

For a claim involving multiple skin cancer diagnoses or a later melanoma diagnosis following an existing non-melanoma award, see our detailed post on amending an existing skin cancer claim.

How Baione Law handles a 9/11 skin cancer claim

Baione Law represents 9/11 skin cancer claimants at every stage:

• Free Case Review. The firm evaluates presence in the exposure zone, exposure category, diagnosis, and current WTCHP certification status. No cost, no obligation.
• Our fee is 10%, paid only from your award. If you don't get paid, neither do we. The 10% cap is set by federal statute.
• WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with WTCHP enrollment to support certification of both non-melanoma and melanoma skin cancers.
• VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, and medical impact evidence.
• Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation required by the VCF, including dermatology records, pathology reports, treatment history, and evidence of any permanent complications.
• Award, appeals, and amendments. After the VCF issues an award, the firm reviews it, files a compensation appeal if warranted (particularly relevant for above-baseline non-melanoma cases), and handles amendments for any subsequent certified diagnoses.